Location Directory

Clinical trials in Detroit, Michigan

This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7245

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Atrial Fibrillation
Interventions: BAY 3670549, Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 5 more

Conditions: Autoimmune Haemolytic Anaemia
Interventions: rilzabrutinib, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 27
States / cities: Phoenix, Arizona • Tucson, Arizona • Duarte, California + 23 more

Conditions: Moderate-to-Severe Atopic Dermatitis
Interventions: Nemolizumab; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 1,935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 136
States / cities: Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 104 more

Conditions: Differentiated Thyroid Cancer
Interventions: Cabozantinib, Placebo; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 16 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 31
States / cities: Newport Beach, California • Sacramento, California • San Francisco, California + 27 more

Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT); Procedure · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2033
U.S. locations: 23
States / cities: Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions: LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 25
States / cities: Duarte, California • Santa Monica, California • Denver, Colorado + 18 more

Conditions: Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
Interventions: Palbociclib, Cemiplimab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen collection, Questionnaire Administration; Drug · Biological · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 194
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 146 more

Conditions: Breast Screening
Interventions: Digital Mammography, Digital Tomosynthesis Mammography, Laboratory Biomarker Analysis; Procedure · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 45 Years to 74 Years · Female only
Enrollment: 108,508 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2029
U.S. locations: 133
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 107 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone, Enzalutamide, Apalutamide, Darolutamide, Deutenzalutamide, Radium-223; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 28
States / cities: Dothan, Alabama • Phoenix, Arizona • Duarte, California + 24 more

Conditions: Mortality Prediction
Interventions: blood sample to check CXCL9 pre stem cell transplant and cell therapy; Diagnostic Test
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
Interventions: RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, RMC-9805; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 29
States / cities: Gilbert, Arizona • Duarte, California • Irvine, California + 24 more

Conditions: Breast Cancer
Interventions: PF-07248144, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 215
States / cities: Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 150 more

Clinical trials in Detroit, Michigan

Filter and sort this location

Live official records

A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

BIO-FUNCTION for Prediction Non Relapse Mortality in Transplant and Cell Therapy

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.